Biotechnology

Bluebird Bio

Luckin

Financial Analysis

BLUE

LKNCY

01364

02555

SBUX

Luckin Coffee announces first buyback

Luckin Coffee

GUMING

CHABAIDAO

Starbucks

LKNCY: Sales Up, Profits Lag — When Will the 'Little Blue Cup' Shake Off the 'Delivery Hangover'?

DXYZ

SATS

AMZN

TSLA

MRLN

RKLB

ASTS

In the prior report, we started with the prospect of a SpaceX listing and mapped the key threads behind the current wave of commercial space opportunities. In this installment, we focus on the main players in reusable rocket launches and satellite operations. We also break down the value chain to assess potential investment opportunities through the lenses of the competitive landscape and value-chain dynamics.

Destiny Tech100

Echostar

Amazon

Tesla

Merlin

Rocket Lab

AST SpaceMobile

SpaceX Challengers: Can Bezos and China Inc. Catch Up?

NVIDIA

Hot topic

NVDA

SSNGY

VERA

002245

On Mar. 16, 2026, Jensen Huang, founder and CEO of NVIDIA, delivered the keynote at GTC 2026.Core themes included the 20th anniversary of the CUDA platform, the inference inflection and a surge in compute demand, the Vera Rubin system architecture, Groq integration, the OpenClaw agent revolution, and physical AI and robotics...

Samsung Electronics 

Vera Therapeutics

Jiangsu Azure Corporation

NVDA GTC: AI's Big Show — High Hopes In, Disappointed Out?---

Commercial Space

SpaceX

Deep Research

AMZU

TSDD

TSLL

TSLQ

09366

07766

07366

TSLR

In the prior report, we used the prospect of a SpaceX IPO as a starting point. We mapped the main contours of the current commercial-space opportunity.In this report, we focus on reusable rocket launches and satellite operations, profiling the major market participants. We also break down the value chain to analyze potential investment opportunities through the lenses of the competitive landscape and each link in the chain.

Direxion Daily AMZN Bull 2X Shares

GraniteShares 2x Short TSLA Daily ETF

Direxion Daily TSLA Bull 2X Shares

AXS TSLA Bear Daily ETF

XI2CSOPTSLA-U

XL2CSOPTSLA

XI2CSOPTSLA

GraniteShares 2x Long TSLA Daily ETF

SpaceX Challengers: Can Bezos and China Inc. Catch Up?

---

CoreWeave

Conference Minutes

CRWV

NVDL

07788

07388

NVDY

NVDD

NVDX

NVDQ

Below is the FY25 Q4 earnings call Trans compiled by Dolphin Research for $Coreweave(CRWV.US). For our earnings take, see 'CoreWeave: Orders Soaring, Profits Plunging—Is the compute unicorn stuck in a profitability trap?'.I. Key financials recap. Cash and marketable securities: $4.2bn as of Dec 31.Financing activities: issued convertible preferred notes in Q4, raising approx. $2.6bn. Expanded the revolving credit facility to $2.5bn. In 2025, secured over $18bn in combined debt and equity financing...

Coreweave

GraniteShares 2x Long NVDA Daily ETF

XL2CSOPNVDA

XI2CSOPNVDA

YieldMax NVDA Option Income Strategy ETF

Direxion Daily NVDA Bear 1X ETF

T-Rex 2X Long NVIDIA Daily Target ETF

T-Rex 2X Inverse NVIDIA Daily Target ETF

CoreWeave (Trans): Massive capex fully backed by signed service contracts

Meta/Facebook

Appraisal value

00700

TCEHY

TCTZF

80700

CASH

HTCD

These days, it's rare to see trillion-dollar giants fluctuating by 10% or 20% in a single day, but Meta is an exception. It took Meta just one quarter to fall from grace. After the Q3 earnings report, investors' panic seemed to have just been digested. Recently, with the expectation of interest rate cuts rising, $Meta Platforms(META.US) has rebounded 10% from the bottom. In terms of narrative, first, Meta has the most extensive application scenarios, and the AI investment process will be accompanied by accelerated revenue, the &#34;AI darling&#34; narrative; then came the Q3 combination of increased investment and slowed revenue growth guidance...

Meta Platforms

TENCENT

Blue Owl Capital

Tencent

Tencent Holdings Limited

TENCENT-R

Pathward Fin

Tencent HK SDR 10to1

"AI Darling" Quickly Becomes a "Spendthrift", Can Meta Make a Comeback?

OpenAI

AVGO

NOA3

ORCL

AMDL

OPEN

BEAT

IONQ

OPENL

OPENW

OPENZ

BEATW

1. Key Points of the GTC Conference 1. NVIDIA has established a strategic partnership with Nokia, investing $1 billion in Nokia's equity. They released a new product series called 'NVIDIA ARC,' which Nokia will use for future base stations to upgrade 6G and AI capabilities; 2. They released the NVQLink interconnect architecture and the CUDAQ platform, which directly connects GPU supercomputers with QPUs (quantum processors), laying the groundwork for quantum computing processors; 3. $NVIDIA(NVDA.US) is collaborating with the U.S. Department of Energy to build the largest AI supercomputer in the United States...

Broadcom

Nokia Oyj

Oracle

GraniteShares 2x Long AMD Daily ETF

Opendoor Tech

HeartBeam

IonQ

Opendoor Tech Series A - CW26

Opendoor Tech Series K - CW26

Opendoor Tech Series Z - CW26

HEARTBEAM INC C/WTS 31/10/2026 (TO PUR COM)

 GTC Conference: Next Year's Shipment 'Blockbuster', is NVIDIA‘s Limit Really “Sky”？

Bluebird Bio Updates Merger Agreement Offering $5 Per Share

Bluebird Bio released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 38.71 M (forecast USD 37.63 M), actual EPS USD -2.9811 (forecast USD -3.508)

Bluebird Exceeds Earnings Expectations in Q1 2025

Bluebird Bio Receives $5 Per Share Acquisition Offer

Bluebird Bio Sees 104.1% Quarterly Revenue Growth

US Stock Index Futures Decline Due to Tariff Policy Concerns, Related Stock Movements Fluctuate

Bluebird Bio's stock price rises 10% due to Ayrmid's acquisition offer

Bluebird Bio Receives Informal Proposal from AYRMID at $4.50 per Share

Bluebird Bio released FY2024 annual earnings on March 27 (EST), actual revenue $83.81M (forecast $73.23M), actual EPS -$24.8441 (forecast -$30.2328)

Bluebird Bio released FY2024 Q4 earnings on March 27 (EST), actual revenue 38.52 M USD (forecast 27.07 M USD), actual EPS -2.9545 USD (forecast -5.8715 USD)

bluebird bio announces 1-for-20 reverse stock split

Bluebird Bio Participates in CMMI Cell and Gene Therapy Access Model, Agreement Deadline by February 28, 2025

FDA Considers Regulatory Action on bluebird bio's Gene Therapy

Bluebird Bio released FY2024 9 Months Earnings on November 14 Pre-Market EST, with actual revenue of USD 45.29 M and EPS of USD -21.9056

Bluebird Bio released FY2024 Q3 earnings on November 14 Pre-Market (EST), actual revenue $10.61M (forecast $18.68M), actual EPS -6.2723 (forecast -0.3687)

Bluebird Bio to Release FY2024 Q3 Earnings on November 14, Pre-Market EST; Forecasted Revenue: 18.68 M USD, EPS: -7.375 USD

Bluebird Bio released FY2024 Q2 earnings on September 27 Pre-Market EST, actual revenue $16.10M (forecast $23.23M), actual EPS -8.4033 (forecast -0.3592)

Bluebird Bio released its FY2024 Semi-Annual Earnings on September 27 Pre-Market (EST), with actual revenue of 34,674,000 USD and an EPS of -15.633

Bluebird Bio's Q4 2025 Earnings Forecast and Price Target Adjustments

Bluebird Bio Launches Restructuring Plan

OPTIMI HEALTH CORP

Silexion Therapeutics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

GCL Global

HCW Biologics

Jupiter Neurosciences

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

SBIO

Cellipont Bioservices has announced a strategic collaboration with BobcatBio to advance macrophage cell therapy for solid tumors. This partnership aims to support the manufacturing of RB-1355, a novel cellular therapy that utilizes patients' macrophages to enhance immune responses against tumors while minimizing reliance on traditional cancer treatments. Early clinical results show RB-1355 is well tolerated and effective without lymphodepleting chemotherapy. The collaboration emphasizes the commitment to delivering innovative therapies to patients in need.

prnewswire

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

iShares US Pharma

VG Health

Direxion S&P Biotech Bull 3X

Propanc Biopharma

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

SPDR S&P Biotech

Avid Bioservices

Mustang Bio

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Crescent Biopharma

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

10:08 ETCellipont Bioservices and BobcatBio Announce Strategic Collaboration to Advance Macrophage Cell Therapy for Solid Tumors

On February 22, 2026, in Oslo, Norway, BlueNord ASA and its partners in the Danish Underground Consortium (DUC) received an invitation from the Danish Ministry of Climate, Energy and Utilities. The invitation is regarding exploration activities with the DUC. The specific details and scope of the exploration were not disclosed.

Unusual Whales

BlueNord received an invitation to explore extending the DUC license announced by the Danish Ministry on Feb. 22, 2026.

Ayrmid Ltd. reported promising real-world data on motixafortide for mobilizing hematopoietic stem cells (HSCs) in patients with sickle cell disease and beta-thalassemia. The study showed that 73% of patients collected sufficient HSCs for gene therapy, with five patients successfully receiving treatment. Motixafortide, a CXCR4 inhibitor, demonstrated effectiveness in patients who previously failed standard mobilization methods. The findings were presented at the 2025 TANDEM meetings, highlighting the potential of motixafortide to enhance access to gene therapies for these conditions.

MorningStar

Bioline RX

Direxion S&P Biotech Bear 3X

Ayrmid Reports Additional New Real-World Data on Motixafortide for Stem Cell Mobilization in Sickle Cell Disease and Beta-Thalassemia

Blue Bird Corporation announced the immediate resignation of Mr. Phil Horlock from its Board of Directors on December 24, 2025. The resignation was not due to any disagreements with the company's operations or policies. Replacement information has not been disclosed.

TradingView

Blue Bird Corp Announces Director Resignation

Blue Trust Inc. reduced its stake in Synovus Financial Corp. by 17.7% in Q3, selling 37,456 shares. The firm now holds 173,929 shares worth $8.54 million. Synovus Financial reported strong Q3 earnings with $1.46 EPS, beating estimates. The stock has a market cap of $7.35 billion and a P/E ratio of 9.88. Analysts have mixed ratings, with some upgrading and others downgrading the stock. The company announced a quarterly dividend of $0.39 per share.

Market Beat

Synovus Financial

Blue Trust Inc. Sells 37,456 Shares of Synovus Financial Corp. $SNV

Bluebird Bio(BLUE.US)